Navigation Links
Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering 'Provocative Question'
Date:9/17/2012

TAMPA, Fla. (Sept. 17, 2012) Robert A. Gatenby, M.D., senior member of Moffitt Cancer Center's Department of Diagnostic Imaging and Integrated Mathematical Oncology, and his colleagues have received a four-year, $2.1 million grant from the National Cancer Institute to carry out pre-clinical research focused on cancer cell drug resistance. Researchers will examine cancer's evolutionary mechanisms of drug resistance and focus on prevention strategies.

The grant (CA170595-01) stems from the NCI's "Provocative Questions" Project. Researchers from across the country were asked to respond to 24 provocative questions in hopes of stimulating the NCI's research communities. The questions focused on specific advances in understanding cancer and cancer control, broad issues on the biology of cancer, the likelihood of progress in less than a decade, and ways to overcome obstacles to achieving long-term goals.

Gatenby answered question 21: "Given the appearance of resistance in response to cell killing therapies, can we extend survival by using approaches that keep tumors static?"

According to the NCI, the question addresses the relationship between drug resistance in cancer treatment and the Darwinian Theory about natural selection and adaptation to selective environmental pressures. In the case of cancer cells, the environmental pressure refers to chemotherapy and survival means becoming resistant to the drugs aimed at killing them.

The question also asks whether an evolutionary approach can create a balance in tumor cells by not creating resistance through attempts to kill cells but, rather, provide an environment where selection forces are weak. Speculation is that under weak selective forces, cancer cells can live in a form of balance, not dying or becoming drug resistant.

Gatenby's approach to treatment is through a term he and his research team coined adaptive therapy.

"Adaptive therapy shifts the treatment paradigm of currently incurable cancers from the maximum tumor cell killing approach to what we might call the use of 'evolutionally enlightened' drug combinations that can stabilize the tumor," Gatenby said. "Our goal is to minimize the probability of the emergence of drug-resistant cancer cells, which are the ultimate cause of current cancer treatment failure and patient death."

The researchers will use breast cancer as their proof-of-concept tumor model, depending on laboratory tests and mouse models of breast cancer to carry out the studies, Gatenby said. They will enlist Positron Emission Tomography imaging to assess tumor chemotherapy resistance. This approach will ultimately inform clinicians about the presence and number of drug-resistant cells in a tumor.

"These approaches will be used to detect and measure tumor resistance and to suggest treatment strategies that prolong the duration of response to conventional breast cancer therapy," explained Gatenby.

Adaptive therapy is designed to promote competition between chemoresistant and chemosensitive cells, and to make the chemoresistant cells "less fit" than their chemosensitive counterparts, added Gatenby and colleagues.

As applied to cancer, natural selection, a key principle of modern biology, suggests that cancer consists of coalitions of distinct "microhabitats," some of which promote evolution of resistance to therapies. These same evolutionary principles of natural selection can be applied to successfully manage cancer, Gatenby said, and this concept is the foundation for adaptive therapy.

For Gatenby and his colleagues, cancer is subject to the evolutionary processes laid out by Charles Darwin in his concept of natural selection, the process by which nature selects certain physical attributes, or phenotypes, to pass on to offspring to better "fit" them to environmental pressures. The environmental pressure here is the cancer cell's microenvironment under attack from drugs aimed at killing cancer cells. Drug resistance routinely develops when cancer cells adapt to the chemotherapy.

"To improve adaptive therapy, we will examine mechanisms to exploit the cost of resistance to both detect resistant populations and also to suppress their proliferation," concluded Gatenby. "We will also study how the addition of estrogen during therapy intervals can be used to increase the fitness and maintain the number of hormonal therapy-sensitive cells."


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt cancer center researchers find novel predictor for MDS progression risk
2. Moffitt researchers say race affect likelihood of finding suitable stem cell donor
3. Moffitt Cancer Center researchers study childhood melanoma characteristics
4. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
5. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
6. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
7. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
8. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
9. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
10. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
11. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. Josh ... Mesa, and Chandler, Arizona. , Dr. Olson says the decision to support ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
(Date:6/24/2016)... New York (PRWEB) , ... June 24, 2016 , ... ... marijuana patients optimize the ingestion of their medication by matching users with high quality ... users to compare pieces with no commitment. , Inhale was founded by two brothers, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology: